Secure Platform, Broad Patents
Three Issued U.S. Patents
U.S. Patent No. 11,202,777 (December 21, 2021)Methods for maintaining opioid efficacy while reducing tolerance, dependence, and withdrawal through dopamine receptor modulation.
U.S. Patent No. 11,925,635 (March 12, 2024)Co-administration strategies and opioid dose reduction through mechanistic targeting of dopamine pathways.
U.S. Patent No. 12,383,551 (August 12, 2025)Combination therapies, dosing regimens, and treatment paradigms that improve outcomes without sacrificing analgesic effectiveness.
Exclusive worldwide license from East Carolina University
Platform Protection
Our patents protect a therapeutic platform, not just a single product. Claims cover:
- Combination opioid + adjunctive therapies
- Pain treatment methods (acute and chronic)
- Dose-reduction strategies
- Dopamine pathway modulation relevant to tolerance and dependence
International Expansion
Strategic patent filings are underway in Europe and Canada, targeting markets with high opioid use, established regulatory pathways, and strong commercial potential.
Built on Validated Science
- Preclinical data showing reduced tolerance and preserved analgesia
- Clinical evidence supporting improved outcomes
- Mechanistic understanding of dopamine-opioid pathway interactions
This alignment between patents, biology, and clinical data strengthens regulatory positioning and commercial value. Durable IP protection supporting both near-term development and long-term platform growth.Contact Us for more information.